Publikationen 03_2010

1. Wex T, Leodolter A, Bornschein J, Kuester D, Kähne T, Kropf S, Albrecht C, Naumann M, Roessner A, Martinez SM. Interleukin 1 beta (IL1B) Gene Polymorphisms Are Not Associated with Gastric Carcinogenesis in Germany. Anticancer Research 2010;30:505-512. 2. Tanzer M, Balluff B, Distler J, Hale K, Leodolter A, Rocken C, Molnar B, Schmid R, Lofton-Day C, Schuster T, Ebert MP. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One 2010;5:e9061. 3. Leodolter A, Labenz J. Ulcers: adjuvant PPIs to prevent major ulcer bleeds. Nat Rev 4. Labenz J, Leodolter A. [Gastro-oesophageal reflux disease]. MMW Fortschr Med 5. Labenz J, Armstrong D, Zetterstrand S, Eklund S, Leodolter A. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis--results from the maintenance phase of the EXPO study. Aliment Pharmacol Ther 2009;29:1165-1171. 6. Jaspersen D, Nocon M, Labenz J, Leodolter A, Richter K, Stolte M, Vieth M, Lind T, Willich SN, Malfertheiner P. Clinical course of laryngo-respiratory symptoms in gastro-oesophageal reflux disease during routine care--a 5-year follow-up. Aliment Pharmacol Ther 2009;29:1172-1178. 7. Labenz J, Armstrong D, Zetterstrand S, Eklund S, Leodolter A. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study. Aliment Pharmacol Ther 2009;29:959-966. 8. Nocon M, Labenz J, Jaspersen D, Leodolter A, Richter K, Vieth M, Lind T, Malfertheiner P, Willich SN. Health-related quality of life in patients with gastro-oesophageal reflux disease under routine care: 5-year follow-up results of the ProGERD study. Aliment Pharmacol Ther 2009;29:662-668. 9. Leodolter A, Zielinski D, Borkenstein D, Crone M, Labenz J. Diagnosis of jejunal diverticulitis by oral single-balloon enteroscopy. Am J Gastroenterol 2008;103:2405-2406. 10. Nocon M, Labenz J, Jaspersen D, Leodolter A, Meyer-Sabellek W, Stolte M, Vieth M, Lind T, Malfertheiner P, Willich SN. Nighttime heartburn in patients with gastroesophageal reflux disease under routine care. Digestion 2008;77:69-72. 11. Labenz J, Leodolter A. [Medication therapeutic strategies for gastro-esophageal reflux disease]. Z Gastroenterol 2007;45:1169-1179. 12. Leodolter A, Penagini R. On-demand therapy is a valid strategy in GERD patients: pros and 13. Labenz J, Nocon M, Lind T, Leodolter A, Jaspersen D, Meyer-Sabellek W, Stolte M, Vieth M, Willich SN, Malfertheiner P. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol 2006;101:2457-2462. 14. Leodolter A, Ebert MP, Peitz U, Wolle K, Kahl S, Vieth M, Malfertheiner P. Prevalence of H pylori associated "high risk gastritis" for development of gastric cancer in patients with normal endoscopic findings. World J Gastroenterol 2006;12:5509-5512. 15. Wex T, Treiber G, Venerito M, Leodolter A, Peitz U, Kuester D, Hritz I, Krueger S, Roessner A, Malfertheiner P. Helicobacter pylori-induced downregulation of the secretory leukocyte protease inhibitor (SLPI) in gastric epithelial cell lines and its functional relevance for H. pylori-mediated diseases. Biol Chem 2006;387:893-901. 16. Hollenz M, Stolte M, Leodolter A, Labenz J. NSAID-associated dyspepsia and ulcers: a prospective cohort study in primary care. Dig Dis 2006;24:189-194. 17. Labenz J, Borkenstein DP, Leodolter A, Riemann JF. [Gastroesophageal reflux disease]. Dtsch 18. Suzuki K, Suzuki I, Leodolter A, Alonso S, Horiuchi S, Yamashita K, Perucho M. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell 2006;9:199-207. 19. Leodolter A, Nocon M, Kulig M, Willich SN, Malfertheiner P, Labenz J. Gastro esophageal reflux disease is associated with absence from work: results from a prospective cohort study. World J Gastroenterol 2005;11:7148-7151. 20. Jaspersen D, Labenz J, Willich SN, Kulig M, Nocon M, Leodolter A, Lind T, Meyer-Sabellek W, Vieth M, Stolte M, Malfertheiner P. Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD study. Dig Liver Dis 2006;38:233-238. 21. Vieth M, Kulig M, Leodolter A, Naucler E, Jaspersen D, Labenz J, Meyer-Sabellek W, Lind T, Willich S, Malfertheiner P, Stolte M. Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus. Aliment Pharmacol Ther 2006;23:313-319. 22. Leodolter A. Barrett's esophagus and cytokine polymorphisms-confusion about the content in the abstract/results section compared to the table given in a recent manuscript. Am J Gastroenterol 2005;100:2814. 23. Schwab M, Klotz U, Hofmann U, Schaeffeler E, Leodolter A, Malfertheiner P, Treiber G. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 2005;78:627-634. 24. Jaspersen D, Leodolter A. [Reflux-associated sleep disorders]. Dtsch Med Wochenschr 25. Leodolter A, Naumann M, Malfertheiner P. Prevention of gastric cancer by Helicobacter pylori eradication. Dig Dis 2004;22:313-319. 26. Nocon M, Kulig M, Leodolter A, Malfertheiner P, Willich SN. Validation of the Reflux Disease Questionnaire for a German population. Eur J Gastroenterol Hepatol 2005;17:229-233. 27. Chen J, Rocken C, Klein-Hitpass L, Gotze T, Leodolter A, Malfertheiner P, Ebert MP. Microarray analysis of gene expression in metastatic gastric cancer cells after incubation with the methylation inhibitor 5-aza-2'-deoxycytidine. Clin Exp Metastasis 2004;21:389-397. 28. Leodolter A, Wolle K, von Arnim U, Kahl S, Treiber G, Ebert MP, Peitz U, Malfertheiner P. Breath and string test: a diagnostic package for the identification of treatment failure and antibiotic resistance of Helicobacter pylori without the necessity of upper gastrointestinal endoscopy. World J Gastroenterol 2005;11:584-586. 29. Labenz J, Jaspersen D, Kulig M, Leodolter A, Lind T, Meyer-Sabellek W, Stolte M, Vieth M, Willich S, Malfertheiner P. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004;99:1652-1656. 30. Westphal S, Kastner S, Taneva E, Leodolter A, Dierkes J, Luley C. Postprandial lipid and carbohydrate responses after the ingestion of a casein-enriched mixed meal. Am J Clin Nutr 2004;80:284-290. 31. Kulig M, Nocon M, Vieth M, Leodolter A, Jaspersen D, Labenz J, Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P, Willich SN. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol 2004;57:580-589. 32. Peitz U, Vieth M, Pross M, Leodolter A, Malfertheiner P. Cardia-type metaplasia arising in the remnant esophagus after cardia resection. Gastrointest Endosc 2004;59:810-817. 33. Peitz U, Raps S, Plein K, Leodolter A, Hotz DJ, Malfertheiner P. [Long-term course of reflux symptoms following Helicobacter pylori eradication]. Dtsch Med Wochenschr 2004;129:671-675. 34. Dominguez-Munoz JE, Martinez SM, Leodolter A, Malfertheiner P. Quantification of pancreatic zinc output as pancreatic function test: making the secretin-caerulein test applicable to clinical practice. Pancreatology 2004;4:57-62. 35. Leodolter A, Wolle K, Peitz U, Schaffranke A, Wex T, Malfertheiner P. Evaluation of a near- patient fecal antigen test for the assessment of Helicobacter pylori status. Diagn Microbiol Infect Dis 2004;48:145-147. 36. Peitz U, Leodolter A, Wex T, Schutze D, Wolle K, Welte T, Gunther T, Schmidt U, Malfertheiner P. Diagnostics of Helicobacter pylori infection in patients with peptic ulcer bleeding. Z Gastroenterol 2004;42:141-146. 37. Buhling F, Koch G, Wex T, Heimburg A, Vieth M, Leodolter A, Roessner A, Ansorge S, Malfertheiner P. Simultaneous detection and differentiation of anti-Helicobacter pylori antibodies by flow microparticle immunofluorescence assay. Clin Diagn Lab Immunol 2004;11:131-136. 38. Leodolter A, Vaira D, Bazzoli F, Schutze K, Hirschl A, Megraud F, Malfertheiner P. European multicentre validation trial of two new non-invasive tests for the detection of Helicobacter pylori antibodies: urine-based ELISA and rapid urine test. Aliment Pharmacol Ther 2003;18:927-931. 39. Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, Lind T, Meyer-Sabellek W, Malfertheiner P, Stolte M, Willich SN. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003;18:767-776. 40. Malfertheiner P, MOssner J, Fischbach W, Layer P, Leodolter A, Stolte M, Demleitner K, Fuchs W. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther 2003;18:615-625. 41. Leodolter A, Glasbrenner B, Wiedeck H, Eberhardt H, Malfertheiner P, Brinkmann A. Influence of Helicobacter pylori infection and omeprazole treatment on gastric regional CO2. Digestion 2003;67:179-185. 42. Jaspersen D, Kulig M, Labenz J, Leodolter A, Lind T, Meyer-Sabellek W, Vieth M, Willich SN, Lindner D, Stolte M, Malfertheiner P. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther 2003;17:1515-1520. 43. Leodolter A, Wolle K, Peitz U, Ebert M, Gunther T, Kahl S, Malfertheiner P. Helicobacter pylori genotypes and expression of gastritis in erosive gastro-oesophageal reflux disease. Scand J Gastroenterol 2003;38:498-502. 44. Malfertheiner P, Kirchner T, Kist M, Leodolter A, Peitz U, Strobel S, Bohuschke M, Gatz G. Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. Aliment Pharmacol Ther 2003;17:1125-1135. 45. Peitz U, Leodolter A, Kahl S, Agha-Amiri K, Wex T, Wolle K, Gunther T, Steinbrink B, Malfertheiner P. Antigen stool test for assessment of Helicobacter pylori infection in patients with upper gastrointestinal bleeding. Aliment Pharmacol Ther 2003;17:1075-1084. 46. Wolle K, Leodolter A, Malfertheiner P, Konig W. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002;51:705-709. 47. Leodolter A, Peitz U, Ebert MP, Agha-Amiri K, Malfertheiner P. Comparison of two enzyme immunoassays for the assessment of Helicobacter pylori status in stool specimens after eradication therapy. Am J Gastroenterol 2002;97:1682-1686. 48. Knippig C, Arand F, Leodolter A, Nilius M, Bayerdorffer E, Klein U, Malfertheiner P. Prevalence of H. pylori-infection in family members of H. pylori positive and its influence on the reinfection rate after successful eradication therapy: a two-year follow-up. Z Gastroenterol 2002;40:383-387. 49. Westphal S, Leodolter A, Kahl S, Dierkes J, Malfertheiner P, Luley C. Addition of glucose to a fatty meal delays chylomicrons and suppresses VLDL in healthy subjects. Eur J Clin Invest 2002;32:322-327. 50. Wolle K, Leodolter A, Malfertheiner P. [Epidemiology and pathogenesis of Helicobacter pylori infection]. Wien Med Wochenschr 2002;152:117-122. 51. Fei G, Ebert MP, Mawrin C, Leodolter A, Schmidt N, Dietzmann K, Malfertheiner P. Reduced PTEN expression in gastric cancer and in the gastric mucosa of gastric cancer relatives. Eur J Gastroenterol Hepatol 2002;14:297-303. 52. Kahl S, Glasbrenner B, Leodolter A, Pross M, Schulz HU, Malfertheiner P. EUS in the diagnosis of early chronic pancreatitis: a prospective follow-up study. Gastrointest Endosc 2002;55:507-511. 53. Peitz U, Sulliga M, Wolle K, Leodolter A, von Arnim U, Kahl S, Stolte M, Borsch G, Labenz J, Malfertheiner P. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 2002;16:315-324. 54. Miehlke S, Kirsch C, Dragosics B, Gschwantler M, Oberhuber G, Antos D, Dite P, Lauter J, Labenz J, Leodolter A, Malfertheiner P, Neubauer A, Ehninger G, Stolte M, Bayerdorffer E. Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). World J Gastroenterol 2001;7:243-247. 55. Ebert MP, Leodolter A, Malfertheiner P. Novel strategies in the prevention of gastric cancer. Hepatogastroenterology 2001;48:1569-1571. 56. Malfertheiner P, Holtmann G, Peitz U, Birkner B, Arnold R, Hotz J, Leodolter A, MOssner J, Robra BP. [Guidelines of the German Society of Digestive and Metabolic Diseases for treatment of dyspepsia]. Z Gastroenterol 2001;39:937-956. 57. Nilius M, Wex T, Muller-Dietz G, Leodolter A, Schilling D, Malfertheiner P. Comparative evaluation of two hemagglutination tests for the detection of anti-Helicobacter pylori antibodies. Diagn Microbiol Infect Dis 2001;41:221-223. 58. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta- analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001;15:1949-1958. 59. Leodolter A, Peitz U, Malfertheiner P. [Healing peptic ulcer disease with therapy of Helicobacter pylori infection--an overview]. Wien Med Wochenschr 2001;151:300-308. 60. Agha-Amiri K, Peitz U, Mainz D, Kahl S, Leodolter A, Malfertheiner P. A novel immunoassay based on monoclonal antibodies for the detection of Helicobacter pylori antigens in human stool. Z Gastroenterol 2001;39:555-560. 61. Gerards C, Leodolter A, Glasbrenner B, Malfertheiner P. H. pylori infection and visceral hypersensitivity in patients with irritable bowel syndrome. Dig Dis 2001;19:170-173. 62. Leodolter A, Wolle K, Malfertheiner P. Current standards in the diagnosis of Helicobacter pylori infection. Dig Dis 2001;19:116-122. 63. Manes G, Dominguez-Munoz JE, Leodolter A, Malfertheiner P. Effect of cisapride on gastric sensitivity to distension, gastric compliance and duodeno-gastric reflexes in healthy humans. Dig Liver Dis 2001;33:407-413. 64. Leodolter A, Agha-Amiri K, Peitz U, Gerards C, Ebert MP, Malfertheiner P. Validity of a Helicobacter pylori stool antigen assay for the assessment of H. pylori status following eradication therapy. Eur J Gastroenterol Hepatol 2001;13:673-676. 65. Leodolter A, Malfertheiner P. [Current diagnostic methods for detection of Helicobacter pylori infection]. Dtsch Med Wochenschr 2001;126:207-209. 66. Leodolter A, Kahl S, Dominguez-Munoz JE, Gerards C, Glasbrenner B, Malfertheiner P. Comparison of two tubeless function tests in the assessment of mild-to-moderate exocrine pancreatic insufficiency. Eur J Gastroenterol Hepatol 2000;12:1335-1338. 67. Yu J, Ebert MP, Miehlke S, Rost H, Lendeckel U, Leodolter A, Stolte M, Bayerdorffer E, Malfertheiner P. alpha-catenin expression is decreased in human gastric cancers and in the gastric mucosa of first degree relatives. Gut 2000;46:639-644. 68. Malfertheiner P, Leodolter A, Peitz U. Cure of Helicobacter pylori-associated ulcer disease through eradication. Baillieres Best Pract Res Clin Gastroenterol 2000;14:119-132. 69. Agha-Amiri K, Mainz D, Peitz U, Kahl S, Leodolter A, Malfertheiner P. Evaluation of an enzyme immunoassay for detecting Helicobacter pylori antigens in human stool samples. Z Gastroenterol 1999;37:1145-1149. 70. Delbende B, Perri F, Couturier O, Leodolter A, Mauger P, Bridgi B, Bizais Y, des Varannes SB, Andriulli A, Galmiche JP. 13C-octanoic acid breath test for gastric emptying measurement. Eur J Gastroenterol Hepatol 2000;12:85-91. 71. Leodolter A, Dominguez-Munoz JE, von Arnim U, Malfertheiner P. Citric acid or orange juice for the 13C-urea breath test: the impact of pH and gastric emptying. Aliment Pharmacol Ther 1999;13:1057-1062. 72. Leodolter A, Dominguez-Munoz JE, von Arnim U, Kahl S, Peitz U, Malfertheiner P. Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am J Gastroenterol 1999;94:2100-2104. 73. Wolle K, Nilius M, Leodolter A, Muller WA, Malfertheiner P, Konig W. Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany. Eur J Clin Microbiol Infect Dis 1998;17:519-521. 74. Manes G, Dominguez-Munoz JE, Hackelsberger A, Leodolter A, Rossner A, Malfertheiner P. Prevalence of Helicobacter pylori infection and gastric mucosal abnormalities in chronic pancreatitis. Am J Gastroenterol 1998;93:1097-1100. 75. Leodolter A, Dominguez-Munoz JE, von Arnim U, Manes G, Malfertheiner P. 13C-urea breath test for the diagnosis of Helicobacter pylori infection. A further simplification for clinical practice. Scand J Gastroenterol 1998;33:267-270. 76. Dominguez-Munoz JE, Leodolter A, Sauerbruch T, Malfertheiner P. A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut 1997;40:459-462.


Comparing rates of psychiatric and behavior disorders in adolescents and young adults with severe intellectual disability with and without autism

Journal of Autism and Developmental Disorders, Vol. 34, No. 2, April 2004 (© 2004) Comparing Rates of Psychiatric and Behavior Disorders in Adolescents and Young Adults with Severe Intellectual Disability with and without Autism Elspeth A. Bradley,1,5 Jane A. Summers,2 Hayley L. Wood,3 and Susan E. Bryson4 Eight males and four females with an Autism Diagnostic Interview-Revised (ADI-R) di

Microsoft word - document

Putting Behind the Pain to Gain Olympic Gold Rowing Canada Aviron and TYLENOL® join forces to get Gold at 2008 Beijing Olympics The road to Olympic Gold is paved with pain, sacrifice, and perseverance. In order to overcome these obstacles and achieve Olympic success, Canadian athletes require a tremendous amount of resources and support. Rowing Canada Aviron is pleased to announce t

Copyright © 2010 Find Medical Article